GDF11 is not the target of luspatercept

Abstract

In this issue of Blood, Guerra et al have excluded that growth differentiation factor 11 (GDF11) is the target of luspatercept, a novel drug that promotes differentiation of terminal erythropoiesis and is under evaluation for treatment of b-thalassemia and low-risk myelodysplastic syndromes (MDSs).